Ultragenyx is trading 4.1% up at $26.04 as investors position ahead of the company’s second-quarter 2026 earnings report scheduled for August 04, 2026.
- Shares are gaining support from a strong rally across the biotech sector and the broader U.S. equity markets.
- Market participants are focused on upcoming data for Crysvita net sales and potential updates regarding the company's clinical pipeline.